Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Etienne Brain

Showing results (81-90 of 139) with videos related to

Pageof 14
Sort By:
NPJ Breast Cancer|July 10, 2025
Advancing equitable access to innovation in breast cancerSeamus O'Reilly, Ines Vaz Luis, Virginie Adam, et al.
Nature Medicine|January 6, 2009
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerPierre Farmer, Hervé Bonnefoi, Pascale Anderle, et al.
Breast Cancer Research : BCR|November 16, 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trialWilliam Jacot, Paul Cottu, Frederique Berger, et al.
International Journal of Cancer|February 24, 2006
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysisJacques-Olivier Bay, Isabelle Ray-Coquard, Jérôme Fayette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancerHans Wildiers, Pieter Heeren, Martine Puts, et al.
European Journal of Radiology|June 17, 2021
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CTGianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, et al.
NPJ Breast Cancer|December 16, 2025
Author Correction: Advancing equitable access to innovation in breast cancerSeamus O'Reilly, Ines Vaz Luis, Virginie Adam, et al.
Cancers|December 24, 2021
Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three CohortsNadia Oubaya, Pierre Soubeyran, Nicoleta Reinald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2023
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized TrialFrançois-Clément Bidard, Nicolas Kiavue, William Jacot, et al.
Cancers|December 11, 2020
Impact of <i>BRCA</i> Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant ChemotherapyBeatriz Grandal, Clémence Evrevin, Enora Laas, et al.
Pageof 14

Showing results (81-90 of 139) with videos related to

Sort By:
Pageof 14
NPJ Breast Cancer|July 10, 2025
Advancing equitable access to innovation in breast cancerSeamus O'Reilly, Ines Vaz Luis, Virginie Adam, et al.
Nature Medicine|January 6, 2009
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerPierre Farmer, Hervé Bonnefoi, Pascale Anderle, et al.
Breast Cancer Research : BCR|November 16, 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trialWilliam Jacot, Paul Cottu, Frederique Berger, et al.
International Journal of Cancer|February 24, 2006
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysisJacques-Olivier Bay, Isabelle Ray-Coquard, Jérôme Fayette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2014
International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancerHans Wildiers, Pieter Heeren, Martine Puts, et al.
European Journal of Radiology|June 17, 2021
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CTGianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, et al.
NPJ Breast Cancer|December 16, 2025
Author Correction: Advancing equitable access to innovation in breast cancerSeamus O'Reilly, Ines Vaz Luis, Virginie Adam, et al.
Cancers|December 24, 2021
Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three CohortsNadia Oubaya, Pierre Soubeyran, Nicoleta Reinald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2023
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized TrialFrançois-Clément Bidard, Nicolas Kiavue, William Jacot, et al.
Cancers|December 11, 2020
Impact of <i>BRCA</i> Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant ChemotherapyBeatriz Grandal, Clémence Evrevin, Enora Laas, et al.
Pageof 14